xMedical Trainees' Publications: Recent submissions
Now showing items 21-40 of 40
-
Length of hospitalisation for people with severe mental illness: is the longer the better? Commentary on… Cochrane Corner
(2021)The Cochrane review in this month’s Cochrane Corner (Babalola 2014) compares short-stay hospital admission to long-stay/standard admission in patients with severe mental illness for a number of outcomes in a total 2030 ... -
Is it time to review NICE guidelines on family therapy for anorexia in young people?
(2020-04)Family therapy is recommended by the National Institute for Health and Care Excellence (NICE) for the management of anorexia nervosa in children and young people, but there is limited evidence to back this recommendation. ... -
Can dietary supplements maintain cognition in mid- to late-life?
(2020-12)Cognitive health, and prevention of its decline to dementia, has risen in prominence with a corresponding exploration of modifiable risk factors to prevent a decline in cognitive health with age. This commentary discusses ... -
Strategies for preventing occupational stress in healthcare workers: past evidence, current problems
(2021)The problem of occupational stress in healthcare workers is hardly new, but effective interventions in this area are lacking despite being sorely needed – especially in the ongoing Covid-19 pandemic. The review ... -
Can we prevent seasonal affective disorder (SAD) with melatonergic agents?
(2020-06)Seasonal affective disorder (SAD) is a recurrent form of major depression, particularly occurring in the winter months with a generally spontaneous remission in spring/summer. The predictable nature of this condition ... -
The tail wagging the dog: the diagnostic accuracy of first rank symptoms COMMENTARY ON… COCHRANE CORNER
(2019-10)Outcomes for people with schizophrenia are improved by expedient diagnosis and specific treatment. ICD-11 and DSM-5 have reduced the importance of Schneider's first rank symptoms (FRS) in the diagnosis of schizophrenia; ... -
Could health-improving interventions address the growing unemployment crisis?
(2021-02)The COVID-19 pandemic is causing unprecedented rates of unemployment. Poorer mental health is a cause and a consequence of unemployment, and job seekers with poorer mental health remain unemployed for longer. The review ... -
How effective is augmentation with psychotherapy as a next-step option for treatment-resistant depression?
(2020-08)Determining the optimum next-step treatment for the numerous patients with depression who do not adequately respond to an initial trial of medication remains a source of uncertainty in clinical practice. Although a number ... -
Antidepressants plus benzodiazepines in major depressive disorder: a clinical dilemma with no recent answers from research
(2020-10)Comorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. Benzodiazepines also have potential to reduce the initial anxiety that may ... -
Valproate in dementia: time to move on? Commentary on…Cochrane Corner
(2019-02)Baillon et al ’s Cochrane review included 430 participants with agitation in dementia from five randomised controlled trials. Overall, the reviewers found that valproate was no better than placebo for the treatment of ... -
Six-month Neurological and Psychiatric Outcomes in 236,379 Survivors of COVID-19
(2021-01)Background. Neurological and psychiatric sequelae of COVID-19 have been reported, but there are limited data on incidence rates and relative risks. Methods. Using retrospective cohort studies and time-to-event analysis, ... -
Are benzodiazepines effective in treating catatonia?
(2020-12)Establishing an evidence base for the clinical management of catatonia is made difficult by the heterogeneous nature of the condition and the limited understanding of its pathophysiology. Benzodiazepines are a mainstay of ... -
Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA
(2020)Background Adverse mental health consequences of COVID-19, including anxiety and depression, have been widely predicted but not yet accurately measured. There are a range of physical health risk factors for COVID-19, but ... -
The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial
(2020-07)Introduction:Major depressive disorder (MDD) is a common affective disorder. Currently established pharmacotherapies lack rapid clinical response, thereby limiting their ability to bring instant relief to patients. A series ... -
A Structural Brain Network of Genetic Vulnerability to Psychiatric Illness
(2020-05)Psychiatry is undergoing a paradigm shift from the acceptance of distinct diagnoses to a representation of psychiatric illness that crosses diagnostic boundaries. How this transition is supported by a shared neurobiology ... -
Mood Homeostasis, Low Mood, and History of Depression in 2 Large Population Samples
(2020-04)Importance Existing therapeutic options are insufficient to tackle the disease burden of depression, and new treatments are sorely needed. Defining new psychotherapeutic targets is challenging given the paucity of coherent ... -
Longitudinal cognitive performance in patients with Bipolar Disorder
(2020-01)Commentary: Neurocognitive impairments are a rather common occurrence in euthymic Bipolar Disorder (BD) patients. Understanding the degree of longitudinal stability of these deficits is vital in the management and treatment ... -
Cyclical Cushing's syndrome and the presentation of a Bipolar Affective state
(2019-12)Affective disorders are relatively frequently observed in patients suffering from endocrine disease. Thus, in Cushing's syndrome, the most common comorbid mental disorder seen is depressive disorder. The rarer cyclical ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ... -
Vortioxetine for depression: the evidence for its current use in the UK: COMMENTARY ON… COCHRANE CORNER
(2018-12-17)The pharmacological treatment of depression is often hampered by side-effects and unsatisfactory response to treatment. Vortioxetine is one of the newest antidepressants on the market, purportedly with a different mechanism ...
